A Phase II Multi Center Study of BGB324 in Combination with Pembrolizumab in Patients with Previously Treated Advanced Adenocarcinoma of the Lung
This is an open-label, multi-center, single arm, phase II study to assess the anti-tumor activity and safety of bemcentinib when given in combination with pembrolizumab in patients with previously treated, advanced adenocarcinoma of the lung.
Rangaswamy Chintapatla, M.D.
- Kadlec Clinic Hematology and Oncology
- Kadlec Research